Management of Infections in Cirrhosis

Overview

This lecture by Prof. Patrick Kamath (Mayo Clinic) addresses the epidemiology, pathophysiology, and clinical management of bacterial infections in patients with cirrhosis, emphasizing the high associated mortality, antimicrobial resistance challenges, and iatrogenic risk factors.

Key Clinical Topics

• Epidemiology and classification of infections in cirrhosis
• Pathophysiology of bacterial translocation and immune dysfunction
• Multi-drug resistant organisms in cirrhosis
• Consequences of infection and progression to organ failure
• Iatrogenic risk factors including PPIs and rifaximin
• Framework for infection management in acute-on-chronic liver failure

Key Learning Points

• Bacterial infections in cirrhosis: account for approximately 25% of all deaths in cirrhosis; 30–50% of hospitalized cirrhotic patients will develop an infection
• Nosocomial infection definition: any infection occurring ≥48 hours after hospitalization; associated with 30–40% in-hospital mortality
• Healthcare-associated infection: hospitalization or inpatient procedure within the previous 6 months
• Most common community-acquired infections: spontaneous bacterial peritonitis (SBP) and urinary tract infections (UTIs)
• Most common nosocomial infections: UTIs and Clostridioides difficile; respiratory infections are common both at admission and as second nosocomial infections
• Four-fold increased risk of nosocomial infection once cirrhosis is established
• Cirrhosis-associated immune dysfunction: results from gut barrier disruption, altered microbiome, bacterial translocation via mesenteric lymph nodes and portal vein, impaired reticuloendothelial clearance, malnutrition, and alcohol-related immune suppression
• Bacterial translocation: transport of bacteria and pro-inflammatory cytokines into systemic circulation, driving systemic inflammation, tissue injury, and organ failure
• Organ failure mechanism: involves neutrophil extracellular traps causing thrombosis, endothelial dysfunction, mitochondrial dysfunction, capillary leak, and tissue hypoperfusion; SIPA3 plays a key role linking inflammation and coagulation
• Organs failing in infection: brain (hepatic encephalopathy), lungs (acute lung injury), liver, kidneys (acute kidney injury), adrenal glands, and immune system
• PPIs: significantly increase risk of serious infections and C. difficile in cirrhosis; H2 receptor antagonists do not carry the same risk
• Rifaximin: appropriate only for patients who have failed lactulose; should not be used as primary prophylaxis during variceal bleeding; recent data suggest rifaximin prophylaxis can induce resistance to daptomycin, a last-resort antibiotic for VRE
• Multi-drug resistance (MDR): defined as resistance to more than three classes of antibiotics; extensively drug-resistant (XDR) organisms respond to only one or two antibiotic classes

Clinical Data & Study Results

• Alina Allen, 2016 (national CDC data): infection rate in cirrhosis without organ failure <10%; with multiple organ failure ~70%; in-hospital mortality 50%; hospitalization length 16 days vs. 8 days for sepsis from other causes; cost approximately five times that of congestive heart failure and 2.5 times that of general sepsis
• Global MDR study (Angeli et al., Italy): one-third of cirrhotic bacterial infections are MDR; 10% are XDR; MDR prevalence 16% in the US vs. 73% in India; XDR 33% in India
• Projected antimicrobial resistance mortality by 2050: 10 million additional deaths globally attributable to multi-drug resistance

Practical Takeaways

• Audit all cirrhotic patients on PPIs; discontinue if no clear indication to reduce infection and C. difficile risk
• Reserve rifaximin for patients who have failed lactulose; avoid indiscriminate prophylactic use given emerging daptomycin resistance
• Classify infections as community-acquired, healthcare-associated, or nosocomial to guide empir